Literature DB >> 7224206

Elevated plasma binding cannot account for the burn-related d-tubocurarine hyposensitivity.

W S Leibel, J A Martyn, S K Szyfelbein, K W Miller.   

Abstract

Hyposensitivity to the nondepolarizing muscle relaxant d-tubocurarine (dTc) has been reported during the treatment of burn injury. The authors present here evidence obtained by the technique of equilibrium dialysis, that a 1.7-fold increase in dTc binding by plasma constituents occurs one to two weeks following burn injury, a timing which coincides with the onset of clinical hyposensitivity to dTc. Plasma drawn from burned patients at least one week post-burn exhibited a mean dTc-binding capacity of 5.7 +/- 0.9 nmol/g total protein compared to 3.4 +/- 0.7 nmol/g for normal plasma at a final free concentration of 0.5 microM (0.34 microgram/ml). Calculation suggests that increased plasma binding can account only for a fraction of the observed hyposensitivity; other unidentified factors must also be involved. The elevated binding capacity of plasma drawn from burned patients seems unrelated to any of the quantitative or gross qualitative changes in plasma protein profile reported here. Preliminary experiments with metocurine (mTc) show directional changes similar to dTc.

Entities:  

Mesh:

Substances:

Year:  1981        PMID: 7224206     DOI: 10.1097/00000542-198105000-00006

Source DB:  PubMed          Journal:  Anesthesiology        ISSN: 0003-3022            Impact factor:   7.892


  9 in total

1.  An extended pharmacokinetic/pharmacodynamic model describing quantitatively the influence of plasma protein binding, tissue binding, and receptor binding on the potency and time course of action of drugs.

Authors:  J H Proost; J M Wierda; D K Meijer
Journal:  J Pharmacokinet Biopharm       Date:  1996-02

2.  Large burns - transatlantic view.

Authors:  S K Szyfelbein
Journal:  J R Soc Med       Date:  1982       Impact factor: 5.344

3.  Neuromuscular blockade with vecuronium in paediatric patients with burn injury.

Authors:  A K Mills; J A Martyn
Journal:  Br J Clin Pharmacol       Date:  1989-08       Impact factor: 4.335

4.  Anaesthetic considerations for major thermal injury.

Authors:  J D Lamb
Journal:  Can Anaesth Soc J       Date:  1985-01

5.  Unusual resistance to pancuronium in severely burned patients: case reports.

Authors:  M Yamashita; T Shiga; A Matsuki; T Oyama
Journal:  Can Anaesth Soc J       Date:  1982-11

6.  Neuromuscular pharmacodynamics of mivacurium in adults with major burns.

Authors:  T-H Han; J A J Martyn
Journal:  Br J Anaesth       Date:  2011-02-24       Impact factor: 9.166

Review 7.  Influence of burns on pharmacokinetics and pharmacodynamics of drugs used in the care of burn patients.

Authors:  Benoit Blanchet; Vincent Jullien; Christophe Vinsonneau; Michel Tod
Journal:  Clin Pharmacokinet       Date:  2008       Impact factor: 6.447

Review 8.  Clinical pharmacokinetics in patients with burns.

Authors:  U Jaehde; F Sörgel
Journal:  Clin Pharmacokinet       Date:  1995-07       Impact factor: 6.447

Review 9.  Clinical pharmacological and therapeutic considerations in general intensive care. A review.

Authors:  M L Farina; M Bonati; G Iapichino; A Pesenti; F Procaccio; L Boselli; M Langer; A Graziina; G Tognoni
Journal:  Drugs       Date:  1987-12       Impact factor: 9.546

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.